Information  X 
Enter a valid email address

Cellexus Biosystems (CBIO)

  Print      Mail a friend

Wednesday 13 February, 2008

Cellexus Biosystems

Cellexus Biosystems reports the Granting of Fun...


February 13th 2008

Cellexus Biosystems reports the Granting of Fundamental Technology UK Patent

The  Board  of Cellexus Biosystems plc (PLUS Markets: CBIO), the specialist in the design, manufacture
and commercialisation of novel disposable technology for growing cells, announces that the Company has
been issued with the British patent GB2433216 covering the core technology for the CellMaker family of
disposable bioreactor and fermentor products.

    (1)     GB2433216.  Cellexus Biosystems plc. Inventor: Auton, K.A. Cell Culture Vessel

Commenting  on  this  granting by the UK Patent Office, the inventor of the CellMaker  technology,  Dr
Kevin Auton, commented:

"The  grant  of this first patent for the Cellexus technology is an important milestone  for  Cellexus
Biosystems  as it provides us with the protection we require to exploit our position in  cell  culture
and  fermentation  and  validates the novelty of our single-use bioreactor  and  fermentors.   We  now
routinely  demonstrate  that  the  CellMaker technology is  as  effective  as  a  traditional  stirred
bioreactor,  even for fermentation, which requires high rates of oxygen transfer.  High mass  transfer
of  oxygen  is achieved without moving parts and is a result of the unique bioreactor geometry.   This
patent will be filed in all major markets and has already been filed in the US".

More  information about the core technology surrounding the CellMaker technology and other  disposable
systems can be can be found on the web site


Further information:

Cellexus Biosystems plc:
Dr Kevin Auton
Chief Operations Director
12 Ramsay Court, Hinchingbrooke Business Park
Huntingdon, Cambridgeshire PE29 6FY
United Kingdom
Tel: +44 1480 451 499
[email protected]

Media enquiries:
Bishopsgate Communications Ltd.
Nick Farmer
+44 (0)20 7562 3350
[email protected]

Trade Press enquiries:
Jessica Auton
+44 1480 352 821
[email protected]

Notes to editors:

Cellexus   Biosystems  sells  high  performance,  single-use,  bioreactors  to  the  biopharmaceutical
industry.   Our products have proven performance advantages and save our customers time,  expense  and
reduce risk. Biopharmaceuticals are molecules made by cells cultured in vessels called bioreactors.
Reducing  the  time  to  market  is  driving  every  biopharmaceutical  company  to  adopt  single-use
technologies.   These  are  less expensive to buy, faster to adopt and have shorter  turnaround  times
between experiments or batches.

The bioreactor systems we sell are:  the CellMaker Lite2(TM) (for bacteria and yeast  cells)  and  the
CellMaker  PLUS(TM)  (a highly sophisticated system for mammalian and insect  cells,  in  addition  to
bacteria  and  yeast).   The  single-use  element is a  medical-grade  bag  in  which  the  cells  are
cultured.   There  are  two variants of these cell culture bags:  CellexusBag(TM)  (bacteria and yeast
cells) and the HybridBagTM (bacteria and yeast cells mammalian cells and insect cells).

Our  vision  is  to be a major supplier of single-use technologies to the biopharmaceutical  industry,
provide  cutting-edge  technologies and to be recognized as a consistent  innovator  in  our  vertical
market.   The  Company  has a wholly owned Subsidiary in the USA.  The majority of  our  products  are
purchased by customers in the USA and EU.

Images of the CellMaker family of products can be downloaded from the Company's website

Cellexus Biosystems PLC


a d v e r t i s e m e n t